Open Nav

Axsome Therapeutics, Inc.

  • Herriot Tabuteau, Axsome Therapeutics, Inc.

Education & Networking

  • Date:Wednesday, October 17
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.
  • Company
  • Company HQ City:New York
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • Ticker:AXSM
  • Exchange:NASDAQ
  • CEO/Top Company Official:Dr. Herriot Tabuteau
  • Year Founded:2012
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :AXS-05 & AXS-02
  • Development Phase of Primary Product:Phase III
Herriot Tabuteau
Axsome Therapeutics, Inc.